← Back to Search

Somatostatin Analog

Octreotide for Neuroendocrine Tumors

Phase 4
Waitlist Available
Led By Nitya Raj, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is comparing two treatments for people with hormonal problems.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Comparison of mean pain scores

Side effects data

From 2013 Phase 3 trial • 429 Patients • NCT00412061
53%
Diarrhoea
51%
Stomatitis
48%
Fatigue
43%
Nausea
43%
Oedema peripheral
41%
Rash
32%
Vomiting
30%
Abdominal pain
30%
Decreased appetite
30%
Headache
27%
Anaemia
27%
Weight decreased
27%
Cough
27%
Dyspnoea
24%
Asthenia
23%
Hypokalaemia
20%
Pyrexia
20%
Dysgeusia
20%
Pruritus
20%
Hyperglycaemia
18%
Arthralgia
16%
Thrombocytopenia
15%
Back pain
15%
Pain in extremity
15%
Epistaxis
14%
Constipation
13%
Dizziness
13%
Aphthous stomatitis
13%
Flatulence
13%
Upper respiratory tract infection
13%
Urinary tract infection
11%
Dry skin
11%
Hypertension
10%
Musculoskeletal pain
10%
Abdominal pain upper
10%
Dry mouth
9%
Oropharyngeal pain
9%
Pneumonitis
9%
Nasopharyngitis
9%
Insomnia
9%
Flushing
8%
Neutropenia
8%
Dehydration
8%
Ascites
8%
Haemorrhoids
8%
Mouth ulceration
8%
Muscle spasms
8%
Musculoskeletal chest pain
8%
Erythema
8%
Hypercholesterolaemia
8%
Hypocalcaemia
7%
Leukopenia
7%
Chills
7%
Hypomagnesaemia
7%
Myalgia
7%
Blood creatinine increased
7%
Dysphagia
7%
Anxiety
7%
Depression
7%
Hyperlipidaemia
6%
Pleural effusion
6%
Abdominal distension
6%
Alopecia
6%
Sinusitis
6%
Dysuria
5%
Pollakiuria
5%
Hypophosphataemia
5%
Aspartate aminotransferase increased
5%
Bronchitis
5%
Onychoclasis
4%
Alanine aminotransferase increased
4%
Hyperhidrosis
4%
Small intestinal obstruction
4%
Pneumonia
4%
Dyspnoea exertional
3%
Pulmonary embolism
3%
General physical health deterioration
2%
Ileus
2%
Renal failure
1%
Colitis
1%
Carcinoid heart disease
1%
Angina pectoris
1%
Small intestinal stenosis
1%
Atrial septal defect
1%
Hypoglycaemia
1%
Cholecystitis acute
1%
Gastroenteritis
1%
Bone pain
1%
Flank pain
1%
Subileus
1%
Cardiac failure
1%
Cardiac failure congestive
1%
Carcinoid syndrome
1%
Abdominal pain lower
1%
Rectal haemorrhage
1%
Malaise
1%
Non-cardiac chest pain
1%
Cachexia
1%
Hypoxia
1%
Interstitial lung disease
1%
Syncope
1%
Renal failure acute
1%
Intestinal obstruction
1%
Cellulitis
1%
Hepatic failure
1%
Sepsis
1%
Metabolic acidosis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo + Octreotide
Everolimus + Octreotide
Everolimus Open Label

Trial Design

2Treatment groups
Experimental Treatment
Group I: Octreotide then LanreotideExperimental Treatment3 Interventions
Each patient on study will receive three injections of intramuscular (IM) octreotide Long Acting Release (LAR). Octreotide LAR for 3 injections followed by lanreotide for 3 injections
Group II: Lanreotide then OctreotideExperimental Treatment3 Interventions
Each patient on study will receive three injections of deep subcutaneous (subq) lanreotide. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Octreotide
2006
Completed Phase 4
~2360
LAR Lanreotide
2017
Completed Phase 4
~60
Questionnaires
2013
Completed Phase 2
~3330

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,933 Previous Clinical Trials
585,326 Total Patients Enrolled
12 Trials studying Neuroendocrine Tumors
436 Patients Enrolled for Neuroendocrine Tumors
Nitya Raj, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
1 Previous Clinical Trials
12 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many medical centers are actively involved in the management of this trial?

"Across 9 distinct clinical trial sites, the research team is recruiting patients. This includes Memorial Sloan Kettering Basking Ridge in Basking Ridge, Memorial Sloan Kettering Monmouth in Commack, and Memorial Sloan Kettering Uniondale. Additionally there are 6 other locations where enrolment is possible."

Answered by AI

What is the current quota for participants in this research?

"This clinical trial is not currently recruiting participants. The original posting was on September 19th 2017 and the latest update took place April 20th 2022. If you are looking for alternatives, there are presently 165 trials related to neuroendocrine tumors that require patients as well as 21 studies regarding Octreotide seeking volunteers."

Answered by AI

Is this trial still actively recruiting participants?

"The clinical trial hosted on clinicialtrials.gov is not currently open to applicants, having last been updated on April 20th 2022 since its original listing in September 2017. However, there are a plethora of other medical studies seeking participants at this moment in time."

Answered by AI

What health issues does Octreotide typically address?

"Octreotide is a useful treatment for neoplasm metastasis, directives of advanced care, and malignancies that involve vasoactive intestinal peptide."

Answered by AI

What past experiments have included Octreotide as an element?

"Currently, 21 separate medical studies are being conducted on Octreotide. 7 of these trials have reached phase 3 with 814 locations offering this medication across Trabzon and Florida."

Answered by AI

Do Octreotide treatments produce any deleterious side effects?

"Due to having been approved, octreotide has a safety rating of 3 on our team's scale. This is because phase 4 trials can only take place after the drug has been declared safe and effective."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
2017. "A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03289741.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top